What section 503A means for compounded peptide prescriptions

Section 503A addresses compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, when statutory conditions are met. The model often responds to a patient-specific medical need. FDA says state boards generally handle day-to-day oversight of state-licensed pharmacies, while FDA can inspect for cause or surveillance. Ask which pharmacy will prepare your medicine and whether it is licensed in your state. FDA: Compounding and the FDA Q&A

Federal conditions restrict which bulk drug substances can be used. A substance may qualify through a recognized monograph, as a component of an approved drug, or through the applicable FDA list; interim policy details and safety categories add complexity. A peptide mentioned in a nomination is not thereby approved for compounding. Ask the prescriber and compounder which legal basis applies to the exact substance and formulation. FDA: 503A bulk substances FDA: Bulk drug substances used in compounding

Even a preparation that meets 503A conditions has not undergone FDA premarket review for safety, effectiveness, and quality. It should be considered when an approved medicine cannot meet a patient’s medical need, as FDA describes. The clinician should explain that reason, the evidence for the proposed use, and how problems will be managed. “Made in a licensed pharmacy” answers a different question from “approved for this condition.” FDA: Compounding and the FDA Q&A

Before dispensing, get the exact ingredient and form, pharmacy contact, prescriber, intended use, patient instructions, and a plan for follow-up. If a seller emphasizes a bulk-substance certificate while hiding the final pharmacy, the care pathway is incomplete. FDA warns that people buying compounded drugs online may not know who prepared them. Keep the label and lot information in your medication record. FDA: Compounding and the FDA Q&A

The prescriber should be able to state why the patient cannot be treated with an available approved product in the proposed situation. FDA gives examples such as an allergy to an ingredient or an inability to use a dosage form. A vague preference for “custom peptides” is not the same explanation. Ask what would be different about the finished compounded preparation and what evidence supports that change. FDA: Compounding and the FDA Q&A

Whether a pharmacist may compound a substance is a legal and regulatory question. Whether the resulting medicine is likely to help this patient is a clinical evidence question. Both need answers. A 503A claim should include the exact ingredient and current basis for using it, while the clinical plan should include a goal, risk discussion, and follow-up. Neither a nomination nor a prescription alone fills both gaps. FDA: 503A bulk substances